Ionis Pharmaceuticals — Jul 29, 2026 release

“Even with the outcome of the CARDIO-TTRansform study of eplontersen in ATTR-CM, our first-half execution and positive outlook for the second half of the year keep us on track to achieve our 2026 financial guidance. We also remain on track to achieve our goal of cashflow breakeven in 2028 and deliver substantial growth and long-term value-creation.”   Recent Highlights - Wholly Owned Medicines • TRYNGOLZA ® (olezarsen), the first FDA-approved treatment to reduce triglycerides and acute pancreatitis risk in adults with severe hypertriglyceridemia (sHTG) as an adjunct to diet   o Generated U.S. net product sales of $5 million and $32 million in the second quarter and first half of 2026, respectively   ■ Demonstrated continued strong demand in FCS, offset by the reduced net price effective April 1, 2026   ■ On track to achieve full year 2026 product sales of $100-110 million, in line with revenues generated in 2025   o sHTG U.S. launch demonstrating early momentum following June 2026 approval   o FCS launch outside the U.S. underway; sHTG marketing application under review in the European Union (EU) with potential launch in 2027   o Results from the CORE and CORE2 open-label extension study (CORE-OLE) will be presented at the European Society of Cardiology (ESC) Congress in August 2026   •